During the last session, Evoke Pharma Inc (NASDAQ:EVOK)’s traded shares were 0.63 million, with the beta value of the company hitting -0.07. At the end of the trading day, the stock’s price was $6.01, reflecting an intraday loss of -1.64% or -$0.1. The 52-week high for the EVOK share is $12.32, that puts it down -104.99 from that peak though still a striking 67.72% gain since the share price plummeted to a 52-week low of $1.94. The company’s market capitalization is $8.97M, and the average intraday trading volume over the past 10 days was 14.36 million shares, and the average trade volume was 2.36 million shares over the past three months.
Evoke Pharma Inc (NASDAQ:EVOK) trade information
Evoke Pharma Inc (EVOK) registered a -1.64% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.64% in intraday trading to $6.01, hitting a weekly high. The stock’s 5-day price performance is 120.96%, and it has moved by 110.88% in 30 days. Based on these gigs, the overall price performance for the year is 35.97%. The short interest in Evoke Pharma Inc (NASDAQ:EVOK) is 17702.0 shares and it means that shorts have 1.01 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies an increase of 66.61% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $18 respectively. As a result, EVOK is trading at a discount of -199.5% off the target high and -199.5% off the low.
Evoke Pharma Inc (EVOK) estimates and forecasts
In the rating firms’ projections, revenue will increase 54.73% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.8M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 4.33M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.55M and 2.65M respectively. In this case, analysts expect current quarter sales to grow by 48.78% and then jump by 62.99% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 42.83%. While earnings are projected to return 64.06% in 2025.
EVOK Dividends
Evoke Pharma Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Evoke Pharma Inc (NASDAQ:EVOK)’s Major holders
Evoke Pharma Inc insiders own 1.34% of total outstanding shares while institutional holders control 16.23%, with the float percentage being 16.45%.
Also, the Mutual Funds coming in first place with the largest holdings of Evoke Pharma Inc (EVOK) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on May 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 6.41 shares. This amounts to just over 0.43 percent of the company’s overall shares, with a $38494.0 market value. The same data shows that the other fund manager holds slightly less at 2.49, or about 0.17% of the stock, which is worth about $14946.0.
